What the FDA labels say about taking them together
Atorvastatin and lonafarnib
Lonafarnib's FDA label of July 2, 2025 names atorvastatin in its contraindications section; the atorvastatin labels PlainMeds reads (2) do not name lonafarnib. The lonafarnib label: “… (“Statins”) Coadministration of ZOKINVY with lovastatin, simvastatin, or atorvastatin is contraindicated. Midazolam Coadministration of ZOKINVY with midazolam is contraindicated. …”
Check it at the source: the atorvastatin FDA label on DailyMed (effective April 15, 2024, Viatris Specialty LLC); the lonafarnib FDA label on DailyMed (effective July 2, 2025, Sentynl Therapeutics, Inc.).
What does the atorvastatin label say about lonafarnib?
Atorvastatin's label (effective April 15, 2024) and its 1 other brand-application label do not name lonafarnib in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Lipitor), NDA020702 (Upjohn), as published by Viatris Specialty LLC, effective April 15, 2024 (SPL set a60cc18b-0631-4cf0-b021-9f52224ece65), via openFDA; the full label on DailyMed
What does the lonafarnib label say about atorvastatin?
Lonafarnib label, contraindicationsCONTRAINDICATIONS ZOKINVY is contraindicated in patients taking: Strong CYP3A inhibitors [see Drug Interactions ( 7.1 )] Strong or moderate CYP3A inducers [see Drug Interactions ( 7.1 )] Midazolam [see Drug Interactions ( 7.2 )] Lovastatin, simvastatin, or atorvastatin [see Drug Interactions ( 7.2 )] Strong CYP3A inhibitors. ( 4 ) Strong or moderate CYP3A inducers. ( 4 ) Midazolam. ( 2.3 , 4 ) Lovastatin, simvastatin, or atorvastatin.
Lonafarnib label, drug interactionsClinically Significant Drug Interactions (Drugs Affected by ZOKINVY) CYP3A Substrates Clinical Impact Lonafarnib is a strong CYP3A mechanism-based inhibitor. Coadministration of ZOKINVY with a CYP3A substrate increases the AUC and C max of the CYP3A substrate [see Clinical Pharmacology ( 12.3 )] which may increase the risk of the CYP3A substrate's adverse reactions, including myopathy or rhabdomyolysis (with statins), or extreme sedation or respiratory depression (with midazolam). Prevention or Management HMG CoA reductase inhibitors (“Statins”) Coadministration of ZOKINVY with lovastatin, simvastatin, or atorvastatin is contraindicated [see Contraindications ( 4 )]. …
Source: FDA drug label (Zokinvy), Sentynl Therapeutics, Inc., effective July 2, 2025 (SPL set 97391d0c-943e-4c5a-8423-68e163aa7f50), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Atorvastatin | Lonafarnib | |
|---|---|---|
| Labeled for | High cholesterol, Angina, High triglycerides, Heart attack and coronary artery disease | n/a |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $0.0228 per tablet 10 mg tablet | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once